Calzada completes treatment in NovoSorb trial
02 April, 2013 by Dylan Bushell-EmblingCalzada’s (ASX:CZD) PolyNovo unit has wrapped up a human trial involving using NovoSorb in vacuum-assisted closure of pressure sores.
Bioniche resumes control of bladder cancer drug
02 April, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) is back in control of commercialisation activities for bladder cancer treatment Urocidin after wrapping up its partnership with Endo Pharmaceuticals.
pSivida’s treatment for chronic diabetic macular edema awaits FDA approval
02 April, 2013pSivida licensee Alimera Sciences has made a resubmission to the US Food and Drug Administration for approval of Iluvien for chronic diabetic macular edema.
Bioniche secures grant for E. coli vaccine project
02 April, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) will receive up to C$500,000 in funding from Canada’s NRC to support the development of a new generation of its E. coli O157 cattle vaccine.
TGA proposes changes to pre-market assessment for medical devices
02 April, 2013AusBiotech’s March industry submission addresses the Therapeutic Goods Administration’s (TGA) proposed changes to the pre-market assessment requirements for medical devices.
Partnership to further develop anticancer formulation
28 March, 2013The University of Wollongong (UOW) has licensed the commercialisation rights to a novel drug formulation for the treatment of metastatic colorectal cancer (mCRC) to a local biotech company - FivePhusion.
Bioniche welcomes Canadian investments in R&D
28 March, 2013Bioniche (ASX:BNO) has lauded decisions by the Canadian government to provide more funding for programs which support R&D and commercialisation efforts by the nation’s companies.
Stem cells and business development feature in March AusBiotech journal
28 March, 2013AusBiotech is pleased to provide the latest edition of the Australasian Biotechnology e-journal (Volume 23, Number 1).
AusBiotech appoints global life sciences fund manager as new board member
26 March, 2013AusBiotech has announced the appointment of Lawrence Gozlan as a non-executive director, bringing to the board global capital markets experience and specialist knowledge in life sciences investing.
Driving innovation
26 March, 2013 by Dr Anna Lavelle, CEO, AusBiotechAusBiotech welcomes the federal government’s Plan for Australian Jobs, which will aid innovative companies and help support the biotechnology sector.
Phosphagenics’ new opioid patch clears phase I
25 March, 2013 by Dylan Bushell-EmblingPhosphagenics’ (ASX:POH) TPM-Oxymorphone patch, its second opioid-based pain patch in development, has met its delivery targets in a phase I trial.
Strong early results from Viralytics melanoma trial
25 March, 2013 by Dylan Bushell-EmblingA lead investigator for Viralytics’ (ASX:VLA) phase II trial of Cavatak in melanoma has presented some preliminary results from his leg of the study.
pSivida partner to resubmit Iluvien NDA this month
25 March, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) has said partner Alimera plans to resubmit Iluvien for US approval in March and that it will receive a $23.9 million milestone payment if the NDA is accepted.
Phylogica gets Australian Phylomer patent
25 March, 2013 by Dylan Bushell-EmblingPhylogica (ASX:PYC) has won an Australian patent covering its Phylomer peptide libraries as a composition of matter.
Alchemia appoints two new board members
22 March, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has added an oncology expert and an international investment banking veteran to its board.
